Risks of Compounded Drugs vs. FDA-approved Versions

Howie and Harlan are joined by Lee Schwamm, associate dean for digital strategy and transformation for Yale School of Medicine and chief digital health officer for Yale New Haven Health System, to discuss how AI and other digital tools can be part of fixing a broken healthcare system. Harlan reports on lightly regulated compounding pharmacies producing anti-obesity drugs; Howie gives an update on efforts by the FDA and CDC to fight bird flu.

Links:

"2023 Paul Dudley White Award: Dr. Lee Schwamm"

Yale School of Medicine | Lisa Leffert, MD

Health & Veritas | Dr. Lisa Leffert: Leading in Anesthesiology

Testimony Prepared by Dr. Lee Schwamm Submitted to the House Committee on Energy and Commerce Subcommittee on Heath

"Ambient AI Is Here, And We Are Blissfully Unaware Of It"

"Yale New Haven Health to provide AI-driven clinical documentation"

"Abridge, Mayo Clinic, And Epic Collaborate To Develop An Integrated Artificial Intelligence Documentation Solution For Nurses"

"Are You Sure Your Ozempic Is Real? Fakes Are on the Rise."

"Bill on Drug Compounding Clears Congress a Year After a Meningitis Outbreak"

CDC | H5 Bird Flu: Current Situation

"Is Bird Flu Spreading Widely to Farm Workers? A Small Study Offers Some Reassurance"

Learn more about the MBA for Executives program at Yale SOM.

Email Howie and Harlan comments or questions.